Accelerating Innovation: Replicate Bioscience And Cytiva Collaborate To Deliver srRNA-LNP Vaccines

In the rapidly evolving world of vaccine development, there's considerable buzz around mRNA and pDNA therapeutics. However, the potential for self-replicating RNA (srRNA) to transform the clinical landscape shouldn't be overlooked. Thanks to its unique ability to replicate itself, srRNA can offer sustained protein expression with lower dosing requirements, fewer side effects, a smaller manufacturing footprint, and reduced costs.

Nevertheless, as with any RNA vaccine, the promise of srRNA technology hinges on a precise delivery system to efficiently transport active payloads to target cells. Replicate Bioscience, a biotechnology company, is dedicated to developing srRNA therapeutics for complex diseases such as cancer and autoimmune disorders. Their advanced srRNA platform distinguishes itself from conventional RNA-based technologies by providing improved efficacy with fewer doses. Recognizing the critical importance of both payload and delivery for the success of srRNA therapeutics, Replicate Bioscience has formed a strategic collaboration with Cytiva.

Explore how integrating their innovative srRNA payload with Cytiva's advanced lipid nanoparticle (LNP) technology, proprietary ionizable lipid portfolio, and extensive LNP experience has driven advances that will accelerate the development of next-generation RNA therapeutics.